New Delhi, August 02, 2018: Drug firm Lupin today said it has received attestation from European Directorate for the Quality of Medicines (EDQM) for its Mandideep facility in Madhya Pradesh. The unit was inspected by EDQM in March this, Lupin said in a statement.
“The inspection was focused on the application for certificate of suitability for the dossier of Cefaclor along with facility inspection for Quality Management Systems based on cGMP as laid under European Union rules governing medicinal products,” it added.
Lupin MD Nilesh Gupta said: “We are happy to receive the EDQM attestation for our Mandideep facility.”
According to the reports published in health.economictimes.indiatimes.com over the past few months, Lupin has continued to drive multiple initiatives to further strengthen manufacturing standards and best practices to be amongst the best, he added.
Lupin stock was trading 1.53 per cent up at Rs 827.90 on BSE in the afternoon.
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…